Abstract
Cystic fibrosis (CF) is an autosomal recessive genetic disorder resulting from genetic defects in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR dysfunction in patients with CF leads to a number of pleiotropic manifestations with the prime pathology being mucus plugging in the airways and paranasal sinuses. Patients with CF are prone to polymicrobial infections and the airway microbiome in such patients changes continuously and evolves over time. The composition of the airway microbiome in CF patients is dependent on a number of factors including geographic variation, type of genetic mutation (e.g., ΔF508), antibiotic exposures, and chronic infection with certain pathogenic bacteria (e.g., Pseudomonas aeruginosa). Proteomic and genomic approaches to understanding the microbiome of patients with CF have provided new insights into the pathogenesis of this disease. High‐throughput pyrosequencing, Sanger sequencing, and phylogenetic microarray analysis have enabled the recognition of multiple lineages and clonal populations of a single bacterial species within the same patient. This provides a unique opportunity to explore novel therapeutic approaches to this disease (for instance, use of probiotics and environmental manipulation) and potentially translate them into bedside clinical interventions.
Keywords
- cystic fibrosis
- microbiome
- dysbiosis
- Pseudomonas aeruginosa
- burkholderia cenocepacia
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene [1]. CF is most prevalent in the Caucasian population and is a common life‐limiting disease [2]. CFTR is expressed on the apical surface of epithelial cells of the respiratory, gastrointestinal, pancreatic and reproductive tracts, and sweat glands [3]. The prime function of CFTR ion channel is to transport chloride ions across epithelial surfaces in order to maintain the osmotic gradient. Chloride ions are actively pumped out into the luminal side of the gastrointestinal and respiratory tracts, which decrease water potential on the luminal side. Subsequently, water molecules move from a higher osmotic potential to a lower osmotic potential (down the osmotic gradient) and combine with mucin glycoproteins to keep them adequately hydrated. This in turn helps to maintain the thin consistency of the mucus layer, which is essential for optimal mucociliary function [4]. Thick and viscid mucus caused by a defect in chloride‐conducting transmembrane channel results in stagnation of mucus. Moreover, CFTR channel also plays an important role in regulating the transepithelial transport of sodium and bicarbonate ions [5]. Defective CFTR functioning leads to an increase in pH of the mucus layer, which compromises the innate immune system and promotes inflammation. Defects in innate immunity and chronic inflammation predispose patients to recurrent pulmonary infections, which result in permanent lung damage—the prime cause of morbidity and mortality [6]. Pulmonary system is not the only organ‐system affected in CF; endocrine, gastrointestinal, and reproductive systems are also involved in this multisystem disorder [3].
The human microbiome project aims to identify and characterize microbial flora of healthy and diseased individuals [7]. Understanding the role of infectious pathogens in the pathogenesis of CF in general and pulmonary exacerbations and lung damage in particular has enabled the scientific community to devise new treatment modalities for CF patients, which can potentially improve outcomes and survival in such patients. In patients with CF, different bacteria inhabit different parts of the lung at various stages of the disease and persistent inflammation in the lungs can change and modify the composition of the microbiome [8]. For instance, methicillin‐sensitive
2. The microbiome
As mentioned previously, the human microbiome project aims to identify and characterize microbial flora of healthy and diseased individuals [7]. There is a diversity of microbes in every single human being i.e., diversity being defined as the number and distribution of a particular type of organism in a body habitat. Every human has particular and distinct microbes; dysbiosis (alteration in composition and balance) of these microbes is now thought to underlie the pathogenesis of many diseases, such as inflammatory bowel disease,
Another example of a disease where microbiota plays a major role in pathogenesis is Crohn's disease. The exact cause of Crohn's disease is unknown; however, evidence suggests that microbiota contribute to the underlying pathology and disease development [17]. No single bacterium has been convincingly shown to contribute to the overall pathogenesis of Crohn's disease. Instead, dysbiosis (bacterial imbalance) is more widely accepted as a leading factor in the disrupted host immune system cross‐talk that results in subsequent intestinal inflammation [18]. Depletion of symbiont (beneficial) microbes (including Firmicutes, Bifidobacteriaceae, and Clostridia) in conjunction with an increase in pathobiont (harmful) microbes (such as Bacteroidetes and Enterobacteriaceae) is a striking feature observed in Crohn's disease. No single factor has been definitely identified as driving this dysbiosis; instead, a host of environmental factors—such as the diet, antibiotic exposures and possible early life infections—in the presence of underlying genetic susceptibilities may contribute to the overall pathogenesis of Crohn's disease [17].
In CF patients, composition of the microbiome of pulmonary and gastrointestinal tracts changes over time, presumably as a consequence of inflammation [19]. Most research studies have demonstrated the influence of inflammation in negatively selecting against potential pathogens. Moreover, some bacterial species may also have the ability to exploit inflammatory byproducts for their benefit, which may promote their natural selection in inflamed habitats [20]. Reactive nitrogen species produced during inflammatory responses can be exploited by pathogens for their growth. Moreover, inflammatory mediators can provide an environment for some bacteria to grow and use these inflammatory mediators for their survival [21]. Examples of such bacteria include
3. Heterogeneity of the CF airway microbiome
Due to defects in innate immunity, CF patients are prone to polymicrobial infections and their airway microbiome changes continuously and evolves over time. The primary cause of death in CF patients is respiratory failure due to persistent and recurrent pulmonary infections with different pathogenic organisms [22]. Over the past decade, the median survival for such patients stands at 37 years despite increases in life expectancy [23]. MSSA and
Microbes of the lower airways in all humans exist in a dynamic state. Literature published on microbiome of CF patients has shown a complex and dynamic interaction between different organisms in the airways of such patients [28]. Organisms within a single patient are genetically and phenotypically diverse and heterogeneity is detectable even in different parts of the same lung. Over a period of time, community diversity of bacteria declines in CF patients as pulmonary function declines and lung disease progressively worsens. Studies have shown that diversity of microbial communities correlates positively with pulmonary function and outcome [29]. Such diversity was previously unrecognized as most studies relied solely on culture‐based methods of culturing bacteria. However, novel state‐of‐the‐art molecular techniques (such as Sanger sequencing of clone libraries, terminal restriction fragment length polymorphism [RFLP] analysis and microarray hybridization) have enabled the detection of subtle molecular diversity among seemingly similar bacterial species [30]. This diversity may be influenced by a number of factors including the patient's age, sex, type of CFTR mutation, antibiotic exposures, environmental factors, and extent and severity of lung disease. In a study by Zhao et al., sputum samples were collected from six CF patients over a period of 10 years. Of a total of 126 sputum samples, 662 operational taxonomic units (OTU) were identified and each patient had 5–114 different OTUs [29]. Similarly, in another observational study, sputum samples of patients with acute infective exacerbation of non‐CF related bronchiectasis were collected. Sputum cultures from each patient contained large quantities of multiple bacterial species with a single predominant pathogenic species [31]. In one study, polymerase chain reaction (PCR)‐temporal temperature gel electrophoresis (PCR‐TTGE) was used to evaluate intraspecific and intragenomic 16S rDNA variability among commonly isolated respiratory pathogens from CF patients [32]. Significant discordance in intraspecific and intragenomic variability was noted among different bacterial species with
4. Composition of the CF microbiome and its determinants
The composition of the airway microbiome in CF patients is dependent on a number of factors including geographic variation (more common in white population), type of genetic mutation (e.g., ΔF508), antibiotic exposures, and chronic infection with certain pathogenic bacteria (e.g.,
The microbiome in patients with CF evolves as patients grow older, and this is a consequence of the wide adaptability of pathogenic bacteria. Clustering of phylogenetically similar bacterial communities and loss of the architectural diversity of the airway microbiome is a key feature of late‐stage CF airway disease. Moreover, the type of bacterial species predominating at a particular age group is also of immense importance. In one study, phylogenetic diversity of CF airway microbiota in patients of different age groups was studied using microarray analysis [35].
In another study [29], CF patients with progressive lung disease were noted to have a decrease in bacterial diversity with increasing age, but the total bacterial density remained stable over time. Antibiotic exposures in conjunction with recurrent pulmonary exacerbations were proposed as a possible contributing factor toward this observation. In a study by Tunney et al., several anaerobic species (including a number of Veillonella and Prevotella species) constituted a significant portion of the CF airway microbiota [36]. In a unique study, next generation sequencing was used to study the microorganisms of gastric juice among patients with CF and non‐CF controls [37]. CF gastric juice was noted to have an abundance of Pseudomonas spp. and a relative paucity of normal gut bacteria (such as Bacteroides and Faecalibacterium), which was in contrast with normal gastric juice samples. These results suggest that CF patients possess a unique aerodigestive microbiome that is inter‐related. This explanation seems plausible as the factors that influence the airway microbiome (for instance, antibiotic exposures) are also likely to influence the microbiota of gut and other organ‐systems of the body [38].
In patients with CF, different bacterial colony morphotypes can be isolated from a single sputum sample. There is some evidence to suggest that these different morphotypes arise from a single bacterial strain [39]. Microbes in the lungs of CF patients are capable of constantly adapting to selection pressures. Some of the mechanisms that enable the evolution of microbes include motility, type III secretion systems, lipopolysaccharide, plasmids (encoding for antibiotic resistance), biofilm formation, small colony variants, quorum sensing, and hypermutability. As a consequence of these mechanisms, different phenotypes arise from a single bacterial species and, over time, a single bacterial strain with dominating features may evolve [40]. Given that different bacterial strains have differing capacities to evolve, multiple lineages of bacterial colonies evolve and coexist [41]. Some studies have shown that complexity of bacterial communities inversely correlates with patient age, antibiotic exposures, and presence of
The interaction among different bacterial colonies has also become a subject of intense research and genomic and proteomic approaches are currently being used to understand their interrelationships. In an experimental study, production of 4‐hydroxy‐2‐heptylquinoline‐N‐oxide (HQNO) by a strain of
In the recent literature, an increasing number of unusual microbes have been reported as the cause of infective exacerbations of CF. Such bacteria include multidrug resistant pathogens like
4.1. Methicillin‐sensitive Staphylococcus aureus
With the widespread use of antistaphylococcal antibiotics, incidence of Gram‐negative infections among CF patients has increased and MSSA has become less common among adult patients. Overall, the most common cause of chronic lung infections in CF patients is
4.2. Methicillin‐resistant Staphylococcus aureus
4.3. Hemophilus influenzae
Similar to the general population, colonization of the upper respiratory tract of CF patients with
4.4. Pseudomonas aeruginosa
The main reservoir of
The effects of
The CF airway provides a pathological milieu and a scaffold for chronic infection with resistant organisms, the most notable of them being
4.5. Burkholderia cepacia complex
More than 60 species belonging to the genus Burkholderia are not pathogenic to humans, but some of the remaining species are implicated in serious infections in CF patients. Using 16S rDNA and recA gene analysis, 17 species of this genus have been grouped together as the Burkholderia cepacia complex (BCC). BCC is a group of virulent pathogens that are frequently implicated in infective exacerbations in CF patients with end‐stage lung disease. Colonization with BCC in CF patients indicates a poor prognosis and has been shown to be associated with a requirement for lung transplantation. This worse prognosis is due to the inherent antibiotic resistance possessed by these organisms and their ability to rapidly spread from patient to patient. In some cases, infection with BCC can lead to the development of cepacia syndrome—a rapid fulminating pneumonia that often leads to bacteremia and sepsis. Given their virulent nature, strict infection control measures are essential to prevent outbreaks of BCC in CF clinics and centers [92]. A report of rapid spread and outbreak of BCC infection was reported in a CF center in Toronto [93]. This center reported the development of cepacia syndrome in many patients, being characterized by rapidly deteriorating pulmonary function, fever, leukocytosis, elevated markers of inflammation, and BCC bacteremia. Furthermore, in another report, cepacia syndrome occurred in approximately 20% of infected patients and had a case fatality rate of 62% [93].
Outside of the BCC group, a few other species of the Burkholderia genus are also implicated in infective exacerbations. These species include
Most infected CF patients harbor genotypically distinct strains of the BCC. Strains of Burkholderiaspp. that are shared by multiple CF patients are very uncommon. This suggests that most Burkholderia infections in CF patients result from acquisition of strains from the natural environment [92, 96]. In this regard,
In the CFF patient registry, prevalence of BCC was reported to have declined from 9% in 1985 to 4% in 2005. Incidence of BCC was also found to be reduced from 1.3% in 1995 to 0.8% in 2005 [69]. This has not changed significantly over the past decade as shown by data published in 2016 [70]. Ramette et al. analyzed 285 confirmed isolates of BCC using restriction analysis of recA and identified seven different BCC species in the environment [98]. Healthcare‐associated outbreaks of BCC infections as a consequence of contaminated medical devices and products (such as mouthwashes, ultrasound gels, skin antiseptics, and medications) have been reported previously. While most of these outbreaks have generally involved non‐CF patients, the potential for developing such outbreaks among CF patients remains a hazard [99]. Infection of the respiratory tract with BCC species in CF patients often results in a chronic persistent infection [100]. In most such cases, a single strain of Burkholderia spp. colonizes the respiratory tract.
Infection with BCC species has been associated with a worse prognosis. In one study, CF patients who were infected with
4.6. Anaerobic bacteria
Anaerobic bacteria have been described in the airways of people with healthy lungs and are generally not considered to be pathogenic. In patients with CF, anaerobic bacteria are persistent members of the lower airway community as the anaerobic conditions (and steep oxygen gradients) in the lower airways provide an ideal environment for their growth [88, 103]. However, in the CF lung, anaerobic bacteria can produce virulence factors and damage the lung parenchyma (perhaps as a consequence of impaired innate immunity), which may worsen pulmonary function and exacerbate the inflammatory response. Short‐chain fatty acids produced by anaerobic bacteria can increase production of interleukin‐8 (IL‐8) by upregulating expression of the short‐chain fatty acid receptor GPR41 [104]. Moreover, in the CF microbiome, anaerobic bacteria can interact with other established pathogens and lead to progressive pulmonary damage [105]. Previously, anaerobic bacteria were thought to be an infrequent cause of CF exacerbation; however, with the advent of novel (culture‐independent) microbial detection methods [106–109], anaerobes have been isolated from more frequently. In one study, 23.8% of sputum specimens from CF patients grew more than 105 colony forming units (CFU) per milliliter of anaerobic bacteria [110]. In another study, 15 genera of obligate anaerobes were identified in 91% of CF patients with counts (CFU/ml) being comparable to that of
4.7. Nontuberculous mycobacteria
Traditionally, the frequency of CF patients infected with NTM has been reportedly low. In the CFF patient registry, the prevalence of NTM infections among CF patients has been estimated to be 2.2%. Nevertheless, the prevalence of NTM has been increasing slowly over the past few decades. The prevalence of NTM infection in 1999 among CF patients was 0.85%, which increased to 2.18% in 2008 [116]. More recent data published in 2016 shows that the prevalence of NTM may be as high as 11.9% [70]. The most common NTM species have been reported to be Mycobacterium avium‐intracellulare (MAI) complex and
4.8. Stenotrophomonas maltophilia
4.9. Achromobacter xylosoxidans
5. Implications for further research
Cystic fibrosis is a monogenetic multisystem disorder, but, pulmonary disease is the leading cause of morbidity and mortality. Recurrent pulmonary infections with pathogenic bacteria can lead to progressive pulmonary damage and eventually lead to death. Therefore, understanding the CF airway microbiome has immense importance for understanding the overall pathology of the disease. Disruption of the CF airway microbiome under the influence of environmental factors and antibiotic exposures is a crucial step in the development of end‐stage pulmonary disease in such patients [40]. Colonization of the lower airways with pathogenic bacteria, such as
As the CF airway microbiome evolves under the influence of antibiotic exposures, microbes undergo a number of mutations and changes in their genome [137]. While these genetic mutations are an evolutionary mechanism for microorganisms (for instance, to acquire resistance to antibiotics), they create potential vulnerabilities that may be exploited in unique therapeutic approaches. Traditionally, the approach to management of CF pulmonary exacerbations has been through employment of antibiotics. While antibiotics are useful in the short run, multidrug resistant microbes eventually evolve and become a challenge to tackle. In view of this, novel approaches to the management of CF pulmonary disease have been proposed, which involve manipulating patients’ microbial consortia [8]. From a theoretical perspective, such an approach aims to maintain the architecture of the CF airway microbiome and avoids the use of antimicrobials, thereby circumventing the problem of destroying the community structure of a patient's microbiome. Such a novel treatment approach is based on the principles of personalized medicine and aims to tailor treatment according to each patient's individual microbiome [138]. By manipulating and restoring the structure of a patient's airway microbiome, the complex metabolomic profile of the patient's sputum (and other body fluids) can be altered, which may have long‐lasting and pleiotropic consequences [139].
Novel treatment approaches for the treatment of CF patients hold theoretical promise, but their practical applicability and clinical efficacy remains to be established [140]. A recent pilot study compared the use of a probiotic (
Abbreviations
ABPA | Allergic bronchopulmonary aspergillosis |
ATS | American Thoracic Society |
BAL | Bronchoalveolar lavage |
BCC | Burkholderia cepacia complex |
CD | Clostridium difficile |
CF | Cystic fibrosis |
CFF | Cystic Fibrosis Foundation |
CFTR | Cystic fibrosis transmembrane conductance regulator |
CFU | Colony forming units |
FAFLP | Fluorescent amplified fragment length polymorphism |
FEF25 | Forced expiratory flow at 25% of vital capacity |
FEV1 | Forced expiratory volume in first second |
FMT | Fecal microbiota transplantation |
HQNO | 4‐Hydroxy‐2‐heptylquinoline‐N‐oxide |
IL‐8 | Interleukin‐8 |
MAI | Mycobacterium avium‐intracellulare |
MRSA | Methicillin‐resistant Staphylococcus aureus |
MSSA | Methicillin‐sensitive Staphylococcus aureus |
NTM | Non‐tuberculous mycobacteria |
OTU | Operational taxonomic units |
PCR | Polymerase chain reaction |
PBP‐2A | Penicillin binding protein‐2A |
PFGE | Pulsed‐field gel electrophoresis |
PMN | Polymorphonuclear leukocyte |
RAPD | Random amplified polymorphic DNA |
RFLP | Restriction fragment length polymorphism |
RNI | Reactive nitrogen intermediates |
ROS | Reactive oxygen species |
VISA | Vancomycin‐intermediate Staphylococcus aureus |
References
- 1.
Dalemans W, Barbry P, Champigny G, et al . Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation.Nature 1991;354 (6354):526-8. - 2.
Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991;46 (12):881-5. - 3.
Elborn JS. Cystic fibrosis. The Lancet 2016;388 (10059):2519-2531. - 4.
Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiological Reviews 1999;79 (1):S23-45. - 5.
Stutts MJ, Canessa CM, Olsen JC, Hamrick M. CFTR as a cAMP‐dependent regulator of sodium channels. Science 1995;269 (5225):847-50. - 6.
de Koff EM, Groot KM, Bogaert D. Development of the respiratory tract microbiota in cystic fibrosis. Current Opinion in Pulmonary Medicine 2016;22 (6):623-8. - 7.
Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nature Reviews Genetics 2012;13 (4):260-70. - 8.
Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Current Opinion in Pediatrics 2011;23 (3):319-24. - 9.
Busquets NP, Baroni MR, Ochoteco MC, Zurbriggen ML, Virgolini S, Meneghetti FG. Bacterial isolates from respiratory samples of pediatric patients with cystic fibrosis and their distribution by ages. Revista Argentina de Microbiologia 2012;45 (1):44-9. - 10.
Salsgiver EL, Fink AK, Knapp EA, et al . Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis.CHEST Journal 2016;149 (2):390-400. - 11.
Paganin P, Fiscarelli EV, Tuccio V, et al . Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function.PLoS ONE 2015;10 (4):e0124348. - 12.
Fredricks DN. The human microbiota: How microbial communities affect health and disease. Hoboken, NJ: John Wiley & Sons; 2013. pp. 3-4. - 13.
Schnorr SL, Sankaranarayanan K, Lewis CM, Warinner C. Insights into human evolution from ancient and contemporary microbiome studies. Current Opinion in Genetics & Development 2016;41 :14-26. - 14.
von Müller L. New aspects on Clostridium difficile infection. Deutsche medizinische Wochenschrift 2016;141 (16):1144-7. - 15.
Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World Journal of Gastroenterology 2016;22 (32):7186-202. - 16.
Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.World Journal of Gastrointestinal Pathophysiology 2015;6 (4):169-80. - 17.
Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An overview of the bacterial contribution to Crohn disease pathogenesis. Journal of Medical Microbiology 2016;65 (10):1049-1059. - 18.
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen L. Dysbiosis of the gut microbiota in disease. Microbial Ecology in Health and Disease 2015;26 :26191. doi: 10.3402/mehd.v26.26191 - 19.
Scales BS, Dickson RP, Huffnagle GB. A tale of two sites: how inflammation can reshape the microbiomes of the gut and lungs. Journal of Leukocyte Biology 2016;100 (5):943-50. - 20.
Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013;138 (1):1-11. - 21.
Spooner R, Yilmaz Ö. The role of reactive‐oxygen‐species in microbial persistence and inflammation. International Journal of Molecular Sciences 2011;12 (1):334-52. - 22.
Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clinical Microbiology Reviews 2002;15 (2):194-222. - 23.
Nathan K, Shteinberg M, Rivlin J. Cystic fibrosis survival trends in carmel medical center. Harefuah 2015;154 (6):373-6. - 24.
Hauser AR, Jain M, Bar‐Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clinical Microbiology Reviews 2011;24 (1):29-70. - 25.
Vu‐Thien H, Moissenet D, Valcin M, Dulot C, Tournier G, Garbarg‐Chenon A. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. European Journal of Clinical Microbiology and Infectious Diseases 1996;15 (11):876-9. - 26.
Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. Journal of Thoracic Disease 2014;6 (3):210-20. - 27.
Fodor AA, Klem ER, Gilpin DF, et al . The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.PLoS ONE 2012;7 (9):e45001. - 28.
Filkins LM, O’Toole GA. Cystic fibrosis lung infections: polymicrobial, complex, and hard to treat. PLoS Pathogens 2015;11 (12):e1005258. - 29.
Zhao J, Schloss PD, Kalikin LM, et al . Decade‐long bacterial community dynamics in cystic fibrosis airways.Proceedings of the National Academy of Sciences 2012;109 (15):5809-14. - 30.
DeAngelis KM, Wu CH, Beller HR, et al . PCR amplification‐independent methods for detection of microbial communities by the high‐density microarray PhyloChip.Applied and Environmental Microbiology 2011;77 (18):6313-22. - 31.
Rogers GB, Zain NM, Bruce KD, et al . A novel microbiota stratification system predicts future exacerbations in bronchiectasis.Annals of the American Thoracic Society 2014;11 (4):496-503. - 32.
Michon AL, Jumas‐Bilak E, Imbert A, et al . Intragenomic and intraspecific heterogeneity of the 16S rRNA gene in seven bacterial species from the respiratory tract of cystic fibrosis patients assessed by PCR‐Temporal Temperature Gel Electrophoresis.Pathologie Biologie 2012;60 (3):e30-5. - 33.
Madan JC, Koestler DC, Stanton BA, et al . Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures.mBio 2012;3 (4):e00251-12. - 34.
Dickson RP, Erb‐Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Review of Respiratory Medicine 2013;7 (3):245-57. - 35.
Cox MJ, Allgaier M, Taylor B, et al . Airway microbiota and pathogen abundance in age‐stratified cystic fibrosis patients.PLoS ONE 2010;5 (6):e11044. - 36.
Tunney MM, Field TR, Moriarty TF, et al . Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.American Journal of Respiratory and Critical Care Medicine 2008;177 (9):995-1001. - 37.
Al‐Momani H, Perry A, Stewart CJ, et al . Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients.Scientific Reports 2016;6 :26985. - 38.
Rodríguez JM, Murphy K, Stanton C, et al . The composition of the gut microbiota throughout life, with an emphasis on early life.Microbial Ecology in Health and Disease 2015;26 :26050. doi: 10.3402/mehd.v26.26050 - 39.
Häussler S. Multicellular signalling and growth of Pseudomonas aeruginosa .International Journal of Medical Microbiology 2010;300 (8):544-8. - 40.
Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D’Argenio DA, et al . Genetic adaptation byPseudomonas aeruginosa to the airways of cystic fibrosis patients.Proceedings of the National Academy of Sciences 2006;103 (22):8487-92. - 41.
Kussmann M, van Bladeren P. The extended nutrigenomics–understanding the interplay between the genomes of food, gut microbes, and human host. Frontiers in Genetics 2011;2 :21. - 42.
Klepac-Ceraj V, Lemon KP, Martin TR, et al . Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics andPseudomonas aeruginosa .Environmental Microbiology 2010;12 (5):1293-303. - 43.
Flanagan JL, Brodie EL, Weng L, et al . Loss of bacterial diversity during antibiotic treatment of intubated patients colonized withPseudomonas aeruginosa .Journal of Clinical Microbiology 2007;45 (6):1954-62. - 44.
Hoffman LR, Déziel E, D’Argenio DA, et al . Selection forStaphylococcus aureus small‐colony variants due to growth in the presence ofPseudomonas aeruginosa .Proceedings of the National Academy of Sciences 2006;103 (52):19890-5. - 45.
De Vrankrijker AM, Wolfs TF, van der Ent CK. Challenging and emerging pathogens in cystic fibrosis. Paediatric Respiratory Reviews 2010;11 (4):246-54. - 46.
Smith AL, Fiel SB, Mayer‐Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.CHEST Journal 2003;123 (5):1495-502. - 47.
Tenover FC, McAllister S, Fosheim G, et al . Characterization of Staphylococcus aureus isolates from nasal cultures collected from individuals in the United States in 2001 to 2004.Journal of Clinical Microbiology 2008;46 (9):2837-41. - 48.
Rosenfeld M, Gibson RL, McNamara S, et al . Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.Pediatric Pulmonology 2001;32 (5):356-66. - 49.
Aldridge KE. Methicillin‐resistant Staphylococcus aureus: clinical and laboratory features. Infection Control 1985;6 (11):461-5. - 50.
Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin‐resistant Staphylococcus aureus. Trends in Microbiology 2001;9 (10):486-93. - 51.
Lo DKH, Hurley MN, Muhlebach MS, Smyth AR. Interventions for the eradication of methicillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database System Review 2015;2015 (2):CD009650. - 52.
Glikman D, Siegel JD, David MZ, et al . Complex molecular epidemiology of methicillin‐resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community‐associated methicillin‐resistantS. aureus .CHEST Journal 2008;133 (6):1381-7. - 53.
Cafiso V, Bertuccio T, Spina D, et al . Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients.European Journal of Clinical Microbiology & Infectious Diseases 2010;29 (10):1277-85. - 54.
Elizur A, Orscheln RC, Ferkol TW, et al . Panton‐Valentine Leukocidin‐positive methicillin‐resistant Staphylococcus aureus lung infection in patients with cystic fibrosis.CHEST Journal 2007;131 (6):1718-25. - 55.
Dasenbrook EC, Merlo CA, Diener‐West M, Lechtzin N, Boyle MP. Persistent methicillin‐resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;178 (8):814-21. - 56.
Cox DW, Kelly C, Rush R, O’Sullivan N, Canny G, Linnane B. The impact of MRSA infection in the airways of children with cystic fibrosis; a case‐control study. Irish Medical Journal 2011;104 (10):305-8. - 57.
Nadesalingam K, Conway SP, Denton M. Risk factors for acquisition of methicillin‐resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. Journal of Cystic Fibrosis 2005;4 (1):49-52. - 58.
Francis JS, Doherty MC, Lopatin U, et al . Severe community‐onset pneumonia in healthy adults caused by methicillin‐resistant Staphylococcus aureus carrying the Panton‐Valentine leukocidin genes.Clinical Infectious Diseases 2005;40 (1):100-7. - 59.
Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin‐resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta‐analysis. Journal of Antimicrobial Chemotherapy 2008;61 (1):26-38. - 60.
Howard AJ, Dunkin KT, Millar GW. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiology and Infection 1988;100 (02):193-203. - 61.
Brawnwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson J. Harrison's principles of internal medicine, 11th edition. New York City, NY: McGraw Hillbook Company; pp. 1995-2001. - 62.
Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Seminars in Respiratory Infections 2002;17 (1):47-56. - 63.
Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. Journal of Infectious Diseases 1999;180 (2):404-9. - 64.
King P. Haemophilus influenzae and the lung (Haemophilus and the lung). Clinical and Translational Medicine 2012;1 (1):10. - 65.
Román F, Cantón R, Pérez‐Vázquez M, Baquero F, Campos J. Dynamics of long‐term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. Journal of Clinical Microbiology 2004;42 (4):1450-9. - 66.
Hector A, Kirn T, Ralhan A, et al . Microbial colonization and lung function in adolescents with cystic fibrosis.Journal of Cystic Fibrosis 2016;15 (3):340-9. - 67.
Rayner RJ, Hiller EJ, Ispahani P, Baker M. Haemophilus infection in cystic fibrosis. Archives of Disease in Childhood 1990;65 (3):255-8. - 68.
Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. Journal of Cystic Fibrosis 2009;8 (6):386-91. - 69.
Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. CHEST Journal 2009;136 (6):1554-60. - 70.
Cystic Fibrosis Foundation Patient Registry. 2015 Annual Data Report. Cystic Fibrosis Foundation (Bethesda, Maryland); pp. 29-34. - 71.
Tümmler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients.Journal of Clinical Microbiology 1991;29 (6):1265-7. - 72.
Fegan M, Francis P, Hayward AC, Fuerst JA. Heterogeneity, persistence, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients.Journal of Clinical Microbiology 1991;29 (10):2151-7. - 73.
O’Carroll MR, Syrmis MW, Wainwright CE, et al . Clonal strains ofPseudomonas aeruginosa in paediatric and adult cystic fibrosis units.European Respiratory Journal 2004;24 (1):101-6. - 74.
Wolz C, Kiosz G, Ogle JW, et al .Pseudomonas aeruginosa cross‐colonization and persistence in patients with cystic fibrosis. Use of a DNA probe.Epidemiology and Infection 1989;102 (02):205-14. - 75.
Jones AM, Govan JR, Doherty CJ, et al . Spread of a multiresistant strain ofPseudomonas aeruginosa in an adult cystic fibrosis clinic.The Lancet 2001;358 (9281):557-8. - 76.
Armstrong DS, Nixon GM, Carzino R, et al . Detection of a widespread clone ofPseudomonas aeruginosa in a pediatric cystic fibrosis clinic.American Journal of Respiratory and Critical Care Medicine 2002;166 (7):983-7. - 77.
Speert DP, Campbell ME, Henry DA, et al . Epidemiology ofPseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada.American Journal of Respiratory and Critical Care Medicine 2002;166 (7):988-93. - 78.
Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis.Journal of Clinical Microbiology 1996;34 (5):1129-35. - 79.
Grothues D, Koopmann U, von der Hardt H, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains.Journal of Clinical Microbiology 1988;26 (10):1973-7. - 80.
Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.Journal of Medical Microbiology 2004;53 (7):609-15. - 81.
Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.Pediatric Pulmonology 1995;19 (1):10-5. - 82.
Kosorok MR, Zeng L, West SE, et al . Acceleration of lung disease in children with cystic fibrosis afterPseudomonas aeruginosa acquisition.Pediatric Pulmonology 2001;32 (4):277-87. - 83.
Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.Pediatric Pulmonology 1992;12 (3):158-61. - 84.
Johansen HK, Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.Thorax 1992;47 (2):109-11. - 85.
Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection.Journal of Cystic Fibrosis 2005;4 :49-54. - 86.
Folkesson A, Jelsbak L, Yang L, et al . Adaptation ofPseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective.Nature Reviews Microbiology 2012;10 (12):841-51. - 87.
Hull J, Vervaart P, Grimwood K, Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997;52 (6):557-60. - 88.
Worlitzsch D, Tarran R, Ulrich M, et al . Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.The Journal of Clinical Investigation 2002;109 (3):317-25. - 89.
Kolpen M, Hansen CR, Bjarnsholt T, et al . Polymorphonuclear leucocytes consume oxygen in sputum from chronicPseudomonas aeruginosa pneumonia in cystic fibrosis.Thorax 2010;65 (1):57-62. - 90.
Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?—A 30-year Cohort study of survival in Danish CF patients after onset of chronicP. aeruginosa lung infection.Pediatric Pulmonology 2004;37 (5):427-32. - 91.
Siegel JD, Rhinehart E, Jackson M, and Chiarello L. 2007 Guideline for isolation precautions and preventing transmission of infectious agents in healthcare settings. American Journal of Infection Control 2007;35 (10 Suppl 2):S65-S164. - 92.
Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.Future Medicine 2007;2 (2):153-64. - 93.
Isles A, Maclusky I, Corey M, et al . Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.The Journal of Pediatrics 1984;104 (2):206-10. - 94.
Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov.Journal of Clinical Microbiology 2002;40 (6):2062-9. - 95.
Coenye T, Laevens S, Willems A, et al . Burkholderia fungorum sp. nov. and Burkholderia caledonica sp. nov., two new species isolated from the environment, animals and human clinical samples.International Journal of Systematic and Evolutionary Microbiology 2001;51 (3):1099-107. - 96.
Mortensen JE, Fisher MC, LiPuma JJ. Recovery of Pseudomonas cepacia and otherPseudomonas species from the environment.Infection Control & Hospital Epidemiology 1995;16 (1):30-2. - 97.
Baldwin A, Mahenthiralingam E, Drevinek P, et al . Environmental Burkholderia cepacia complex isolates in human infections.Emerging Infectious Diseases 2007;13 (3):458-61. - 98.
Spilker T, Baldwin A, Bumford A, Dowson CG, Mahenthiralingam E, LiPuma JJ. Expanded multilocus sequence typing for Burkholderia species. Journal of Clinical Microbiology 2009;47 (8):2607-10. - 99.
Pegues CF, Pegues DA, Ford DS, et al . Burkholderia cepacia respiratory tract acquisition: epidemiology and molecular characterization of a large nosocomial outbreak.Epidemiology and Infection 1996;116 (3):309-17. - 100.
Yang JH, Spilker T, LiPuma JJ. Simultaneous coinfection by multiple strains during Burkholderia cepacia complex infection in cystic fibrosis. Diagnostic Microbiology and Infectious Disease 2006;54 (2):95-8. - 101.
Kalish LA, Waltz DA, Dovey M, et al . Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.American Journal of Respiratory and Critical Care Medicine 2006;173 (4):421-5. - 102.
Courtney JM, Dunbar KE, McDowell A, et al . Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults.Journal of Cystic Fibrosis 2004;3 (2):93-8. - 103.
Yoon SS, Hennigan RF, Hilliard GM, et al .Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis.Developmental Cell 2002;3 (4):593-603. - 104.
Mirković B, Murray MA, Lavelle GM, et al . The role of short‐chain fatty acids, produced by anaerobic bacteria, in the cystic fibrosis airway.American Journal of Respiratory and Critical Care Medicine 2015;192 (11):1314-24. - 105.
Sherrard LJ, Bell SC, Tunney MM. The role of anaerobic bacteria in the cystic fibrosis airway. Current Opinion in Pulmonary Medicine 2016;22 (6):637-43. - 106.
Bittar F, Richet H, Dubus JC, et al . Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients.PLoS ONE 2008;3 (8):e2908. - 107.
Kolak M, Karpati F, Monstein HJ, Jonasson J. Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. International Journal of Medical Microbiology 2003;293 (4):309-17. - 108.
Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. Journal of Clinical Microbiology 2004;42 (11):5176-83. - 109.
Rogers GB, Carroll MP, Serisier DJ, et al . Bacterial activity in cystic fibrosis lung infections.Respiratory Research 2005;6 (1):49. - 110.
Jewes LA, Spencer RC. The incidence of anaerobes in the sputum of patients with cystic fibrosis. Journal of Medical Microbiology 1990;31 (4):271-4. - 111.
Worlitzsch D, Rintelen C, Böhm K, et al . Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.Clinical Microbiology and Infection 2009;15 (5):454-60. - 112.
O’Neill K, Bradley JM, Johnston E, et al . Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis.PLoS ONE 2015;10 (5):e0126980. - 113.
Harris JK, de Groote MA, Sagel SD, et al . Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.Proceedings of the National Academy of Sciences 2007;104 (51):20529-33. - 114.
Carmody LA, Zhao J, Schloss PD, et al . Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.Annals of the American Thoracic Society 2013;10 (3):179-87. - 115.
Lim YW, Schmieder R, Haynes M, et al . Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data.PLoS ONE 2013;8 (5):e64285. - 116.
LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clinical Microbiology Reviews 2010;23 (2):299-323. - 117.
Olivier KN, Weber DJ, Wallace Jr RJ, et al . Nontuberculous mycobacteria: I: multicenter prevalence study in cystic fibrosis.American Journal of Respiratory and Critical Care Medicine 2003;167 (6):828-34. - 118.
Pierre‐Audigier C, Ferroni A, Sermet‐Gaudelus I, et al . Age‐related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis.Journal of Clinical Microbiology 2005;43 (7):3467-70. - 119.
Levy I, Grisaru‐Soen G, Lerner‐Geva L, et al . Multicenter cross‐sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel.Emerging Infectious Diseases 2008;14 (3):378-84. - 120.
Samra Z, Kaufman L, Pitlik S, Shalit I, Bishara J. Emergence of Mycobacterium simiae in respiratory specimens. Scandinavian Journal of Infectious Diseases 2005;37 (11-12):838-41. - 121.
Qvist T, Taylor‐Robinson D, Waldmann E, et al . Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis.Journal of Cystic Fibrosis 2016;15 (3):380-5. - 122.
Park IK, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis and non‐cystic fibrosis bronchiectasis. Seminars in Respiratory and Critical Care Medicine 2015;36 (2):217-224. - 123.
Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia andAchromobacter (Alcaligenes )xylosoxidans from patients with cystic fibrosis.Journal of Clinical Microbiology 2001;39 (10):3597-602. - 124.
Marzuillo C, de Giusti M, Tufi D, et al . Molecular characterization of Stenotrophomonas maltophilia isolates from cystic fibrosis patients and the hospital environment.Infection Control & Hospital Epidemiology 2009;30 (08):753-8. - 125.
Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case‐control study of predisposing factors. Infection Control & Hospital Epidemiology 1990;11 (3):134-8. - 126.
Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotropho-monas maltophilia as an important nosocomial pathogen.Journal of Chemotherapy 1999;11 (1):28-33. - 127.
Denton M, Todd NJ, Littlewood J. Role of anti‐pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.European Journal of Clinical Microbiology and Infectious Diseases 1996;15 (5):402-5. - 128.
Marchac V, Equi A, Le Bihan‐Benjamin C, Hodson M, Bush A. Case‐control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients.European Respiratory Journal 2004;23 (1):98-102. - 129.
Ritz N, Ammann RA, Casaulta‐Aebischer C, Schoeni‐Affolter F, Schoeni MH. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. European Journal of Pediatrics 2005;164 (9):577-82. - 130.
Waters V, Yau Y, Prasad S, et al .Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.American Journal of Respiratory and Critical Care Medicine 2011;183 (5):635-40. - 131.
Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients.Journal of Cystic Fibrosis 2013;12 (5):482-6. - 132.
Klinger JD, Thomassen MJ. Occurrence and antimicrobial susceptibility of gram‐negative nonfermentative bacilli in cystic fibrosis patients. Diagnostic Microbiology and Infectious Disease 1985;3 (2):149-58. - 133.
Swenson CE, Sadikot RT. Achromobacter respiratory infections. Annals of the American Thoracic Society 2015;12 (2):252-8. - 134.
Hansen CR, Pressler T, Ridderberg W, Johansen HK, Skov M. Achromobacter species in cystic fibrosis: cross‐infection caused by indirect patient‐to‐patient contact. Journal of Cystic Fibrosis 2013;12 (6):609-15. - 135.
Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. Journal of Cystic Fibrosis 2013;12 (2):170-6. - 136.
Firmida MC, Pereira RH, Silva EA, Marques EA, Lopes AJ. Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis. Brazilian Journal of Medical and Biological Research 2016;49 (4):e5097. - 137.
Price KE, Hampton TH, Gifford AH, et al . Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation.Microbiome 2013;1 :27. - 138.
Quinn RA, Lim YW, Mak TD, et al . Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease.PeerJ 2016;4 :e2174. - 139.
Quinn RA, Phelan VV, Whiteson KL, et al . Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome.The ISME Journal 2016;10 :1483-98. - 140.
Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: a systematic review. Journal of Cystic Fibrosis 2016; Epub ahead of print. doi: 10.1016/j.jcf.2016.09.004 - 141.
Bruzzese E, Raia V, Spagnuolo MI, et al . Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study.Clinical Nutrition 2007;26 (3):322-8. - 142.
Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatric Pulmonology 2010;45 (6):536-40. - 143.
Ananthan A, Balasubramanian H, Rao S, Patole S. Probiotic supplementation in children with cystic fibrosis—a systematic review. European Journal of Pediatrics 2016;175 (10):1255-66. - 144.
Janahi IA, Rehman A. Clinical manifestations of cystic fibrosis and their management. In: Cystic and Idiopathic Pulmonary Fibrosis: Risk Factors, Management and Long‐Term Health Outcomes. Robertson L (ed). Hauppauge, NY: Nova Publishers, Inc. 2016; pp.1-56.